Comera Life Sciences, a bio-innovative biologic medicines developer, went public via a SPAC merger with OTR Acquisition, a special purpose acquisition company, in a $258m deal. “There is tremendous opportunity in this multi-billion dollar market to transform the patient treatment experience. We are excited to welcome OTR as partners through this transaction and look forward to our evolution as a public company. This will play a key role in advancing our innovative platform, pipeline, and partnerships to provide essential biologic medicines in subcutaneous forms,” Jeff Hackman, Comera President and CEO.